Annual General Meeting of Lumito AB (publ) 2019

The annual general meeting of Lumito AB (publ), held in Lund on 4 June 2019, passed the following resolutions.

Resolution on approval of the income statement and balance sheet, etc.

The annual general meeting resolved to approve the income statement and balance sheet for the financial year 2018. The Board of Directors and the Managing Director were discharged from liability for the financial year 2018. The meeting further resolved that no dividends are to be paid for the financial year 2018.

Election of board members and auditors

The annual general meeting resolved to re-elect Board members Masoud Khayyami, Stefan Andersson-Engels and Urban Widén. Ulf Bladin and Roland Andersson were elected as new Board members. Masoud Khayyami was re-elected as Chairman of the Board.

The registered audit firm Öhrlings PricewaterhouseCoopers AB was elected as the company's auditor, until the end of the annual general meeting 2020.

Determination of the fees for the Board of Directors and the auditors

The annual general meeting resolved that directors' fees of four times the price base amount shall be paid to the Chairman of the Board, and of two times the price base amount to each of the other Board members. No fee shall be paid to Board members employed by the company.

Remuneration to the auditor shall be paid on open account.

Resolution on authorization for the Board of Directors to resolve on new issues of shares, warrants and convertibles

The annual general meeting resolved to authorize the Board of Directors, on one or multiple occasions and in accordance with the stipulations in the Company's Articles of Association, to resolve on new issue of shares, warrants and/or convertibles in order to increase the Company's share capital. The Board of Directors shall be able to resolve on new issue of shares, warrants and/or convertibles with deviation from the share holders' preferential rights, and/or with payment by set-off, payment-in-kind, or otherwise with particular terms and conditions in accordance with the Swedish Companies Act (2005:551) 2 ch. 5 s. second paragraph 1-3 and 5. Any issue in accordance with this authorization shall be on market conditions, subject to a market-based issue discount when applicable.

For more information contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, sn@lumito.se

Lumito in brief
Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito´s IPR covers imaging with high quality of for instance tissue samples, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. Lumito has an agreement with TTP plc (The Technology Partnership) in Cambridge, UK, regarding development of instruments and staining reagents. Lumito’s share Lumito and warrant Lumito TO1 are traded at the NGM Nordic MTF marketplace.

Subscribe